Advertisement

Topics

BioMarin submits Pegvaliase BLA to FDA for treatment of phenylketonuria

05:41 EDT 4 Jul 2017 | Pharmaceutical Business Review

BioMarin Pharmaceutical has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for pegvaliase, a PEGylated recombinant phenylalanine ammonia lyase enzyme product, to reduce blood phenylalanine (Phe) levels in adult patients with PKU who have uncontrolled blood Phe levels on existing management.

Original Article: BioMarin submits Pegvaliase BLA to FDA for treatment of phenylketonuria

NEXT ARTICLE

More From BioPortfolio on "BioMarin submits Pegvaliase BLA to FDA for treatment of phenylketonuria"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...